Astrazeneca ADR Stock
€71.50
Your prediction
Astrazeneca ADR Stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
Cons
Performance of Astrazeneca ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Astrazeneca ADR | 0.000% | -2.721% | -3.378% | 15.323% | 16.260% | 39.105% | - |
GSK plc ADR | 0.560% | -1.657% | -6.806% | 8.537% | 5.952% | -16.725% | -22.777% |
Bayer AG ADR | - | 1.600% | -14.765% | -49.200% | -26.163% | -50.000% | -57.947% |
Novo Nordisk A/S ADR | 1.150% | -4.059% | 0.775% | -10.959% | 38.593% | 81.564% | 182.609% |
News
3 No-Brainer Stocks to Buy for Under $100 Right Now
A low price doesn't necessarily mean low quality. That's true with lots of products and services. And it's true with stocks, too.
We asked Three Motley Fool contributors to name no-brainer
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global